株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

水虫(足白癬):パイプライン製品の分析

Tinea pedis (Athlete Foot) - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 213129
出版日 ページ情報 英文 50 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.92円で換算しております。
Back to Top
水虫(足白癬):パイプライン製品の分析 Tinea pedis (Athlete Foot) - Pipeline Review, H2 2016
出版日: 2016年12月30日 ページ情報: 英文 50 Pages
概要

水虫(足白癬)は足部で一般的に見られる感染症で、白癬菌という真菌により発症します。主な症状として、足裏の皮膚の乾燥化・剥離や、足部の臭気、足裏に生じる小さく痒い水疱などが挙げられます。主な治療法には抗真菌薬などがあります。

当レポートでは、世界各国での水虫(足白癬)治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 分析範囲

水虫(足白癬)の概要

治療薬の開発

  • 水虫向けパイプライン製品:概要
  • 水虫向けパイプライン製品:比較分析

各企業で開発中の水虫治療薬

パイプライン製品の概略

  • 治験段階の製品
  • 初期段階の製品

水虫治療薬:開発中の製品の一覧(企業別)

水虫治療薬の開発に従事している企業

  • Actavis plc
  • Helix BioMedix, Inc.
  • Anacor Pharmaceuticals, Inc.
  • Viamet Pharmaceuticals, Inc.

水虫:治療薬の評価

  • 単剤治療薬の場合
  • 標的別
  • 作用機序別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

  • アルバコナゾール
    • 製品概要
    • 機能メカニズム
    • 研究開発(R&D)の進展状況
  • VT-1161
  • AN-2718
  • HB-1275
  • クエン酸二水素銀

水虫治療薬:パイプライン製品の最新動向

水虫治療薬:開発が休止状態の製品

水虫関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース(全3件)

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8894IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Tinea pedis (Athlete Foot) - Pipeline Review, H2 2016, provides an overview of the Tinea pedis (Athlete Foot) (Infectious Disease) pipeline landscape.

Athlete's foot, also known as tinea pedis, is a common foot infection caused by fungi called dermatophytes. Symptoms include dry flaking skin on the soles of the feet, unpleasant foot odour and small itchy bubbles or blisters on the soles of the feet. Treatment includes antifungal medicines.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Tinea pedis (Athlete Foot) - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Tinea pedis (Athlete Foot) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Tinea pedis (Athlete Foot) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Tinea pedis (Athlete Foot) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 1, 3 and 1 respectively.

Tinea pedis (Athlete Foot) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Tinea pedis (Athlete Foot) (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Tinea pedis (Athlete Foot) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Tinea pedis (Athlete Foot) (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Tinea pedis (Athlete Foot) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Tinea pedis (Athlete Foot) (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Tinea pedis (Athlete Foot) (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Tinea pedis (Athlete Foot) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • List of Tables
  • List of Figures
  • Introduction
  • Global Markets Direct Report Coverage
  • Tinea pedis (Athlete Foot) Overview
  • Therapeutics Development
  • Pipeline Products for Tinea pedis (Athlete Foot) - Overview
  • Tinea pedis (Athlete Foot) - Therapeutics under Development by Companies
  • Tinea pedis (Athlete Foot) - Pipeline Products Glance
  • Late Stage Products
  • Clinical Stage Products
  • Early Stage Products
  • Tinea pedis (Athlete Foot) - Products under Development by Companies
  • Tinea pedis (Athlete Foot) - Companies Involved in Therapeutics Development
  • Anacor Pharmaceuticals Inc
  • Astellas Pharma Inc
  • Biolab Farmaceutica Ltda
  • Blueberry Therapeutics Ltd
  • Dermala Inc
  • Helix BioMedix Inc
  • Novan Inc
  • Novoteris LLC
  • Sol-Gel Technologies Ltd
  • Viamet Pharmaceuticals Inc
  • Tinea pedis (Athlete Foot) - Therapeutics Assessment
  • Assessment by Monotherapy Products
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Drug Profiles
  • AN-2718 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AS-2077715 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BB-2603 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • dapaconazole - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Drug for Athlete's Foot - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • E-06 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • HB-1275 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • nitric oxide - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SB-208 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • VT-1161 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Tinea pedis (Athlete Foot) - Dormant Projects
  • Tinea pedis (Athlete Foot) - Product Development Milestones
  • Featured News & Press Releases
  • Jul 21, 2016: Novan Announces First Patient Dosed in Phase 2 Anti-Fungal Program
  • Jul 15, 2015: Viamet to Present at American Podiatric Medical Association 2015 Annual Scientific Meeting
  • Jul 09, 2014: Viamet Reports Additional Positive Interim Results of Phase 2 Studies of VT-1161 with Moderate to Severe Interdigital Tinea Pedis
  • Mar 12, 2014: Viamet Reports Positive Interim Results of Phase 2 Interdigital Tinea Pedis Study of VT-1161
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Tinea pedis (Athlete Foot), H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Tinea pedis (Athlete Foot) - Pipeline by Anacor Pharmaceuticals Inc, H2 2016
  • Tinea pedis (Athlete Foot) - Pipeline by Astellas Pharma Inc, H2 2016
  • Tinea pedis (Athlete Foot) - Pipeline by Biolab Farmaceutica Ltda, H2 2016
  • Tinea pedis (Athlete Foot) - Pipeline by Blueberry Therapeutics Ltd, H2 2016
  • Tinea pedis (Athlete Foot) - Pipeline by Dermala Inc, H2 2016
  • Tinea pedis (Athlete Foot) - Pipeline by Helix BioMedix Inc, H2 2016
  • Tinea pedis (Athlete Foot) - Pipeline by Novan Inc, H2 2016
  • Tinea pedis (Athlete Foot) - Pipeline by Novoteris LLC, H2 2016
  • Tinea pedis (Athlete Foot) - Pipeline by Sol-Gel Technologies Ltd, H2 2016
  • Tinea pedis (Athlete Foot) - Pipeline by Viamet Pharmaceuticals Inc, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Tinea pedis (Athlete Foot) - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Tinea pedis (Athlete Foot), H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top